BIOFRONTERA INC (BFRI) Stock Price, Forecast & Analysis
NASDAQ:BFRI • US09077D2099
BFRI Key Statistics, Chart & Performance
The current stock price of BFRI is 0.91 USD. In the past month the price decreased by -0.31%. In the past year, price decreased by -25.23%.
BFRI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BFRI. When comparing the yearly performance of all stocks, BFRI is a bad performer in the overall market: 76.17% of all stocks are doing better.
BFRI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BFRI. BFRI may be in some trouble as it scores bad on both profitability and health.
BFRI Financial Highlights
Over the last trailing twelve months BFRI reported a non-GAAP Earnings per Share(EPS) of -1.91. The EPS increased by 66.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -113.99% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BFRI Forecast & Estimates
8 analysts have analysed BFRI and the average price target is 6.12 USD. This implies a price increase of 572.53% is expected in the next year compared to the current price of 0.91.
For the next year, analysts expect an EPS growth of 64.69% and a revenue growth 3.66% for BFRI
BFRI Ownership
BFRI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.31 | 979.461B | ||
| JNJ | JOHNSON & JOHNSON | 20.94 | 586.255B | ||
| MRK | MERCK & CO. INC. | 22.31 | 301.739B | ||
| PFE | PFIZER INC | 9.14 | 155.618B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.77 | 122.858B | ||
| ZTS | ZOETIS INC | 18.66 | 55.333B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.69 | 26.212B | ||
| VTRS | VIATRIS INC | 6.28 | 18.129B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.79 | 12.352B | ||
| AXSM | AXSOME THERAPEUTICS INC | 225.65 | 9.24B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BFRI
Company Profile
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 92 full-time employees. The company went IPO on 2021-10-14. The firm specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The firm commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
Company Info
BIOFRONTERA INC
120 Presidential Way,, Suite 330
Woburn MASSACHUSETTS US
CEO: Erica Monaco
Employees: 92
Phone: 17812451325
BIOFRONTERA INC / BFRI FAQ
What does BFRI do?
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 92 full-time employees. The company went IPO on 2021-10-14. The firm specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The firm commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
What is the current price of BFRI stock?
The current stock price of BFRI is 0.91 USD. The price increased by 9.64% in the last trading session.
Does BFRI stock pay dividends?
BFRI does not pay a dividend.
What is the ChartMill technical and fundamental rating of BFRI stock?
BFRI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for BFRI stock?
8 analysts have analysed BFRI and the average price target is 6.12 USD. This implies a price increase of 572.53% is expected in the next year compared to the current price of 0.91.
How is the valuation of BIOFRONTERA INC (BFRI) based on its PE ratio?
BIOFRONTERA INC (BFRI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.91).